"What his arguments came down to was this. Stuff the poor countries, because their per capita income is too low to pay for the drugs, and no one lives long enough to need them anyway. Ignore the richest countries, because the smart money there is on clone-tech and tissue replacement banks. In the future the very rich will never grow old anyway. His position—and this is where he got really excited for just a few minutes—is that smart investors will focus on the middle group. That group can’t afford the real cutting-edge work, but who has enough money and enough crumblies to become a sound market for the cheaper viral repair agents.